Enhancing Organ Preservation With Nanoemulsions

This blog highlights the main findings from the research paper Perfluorocarbon Nanoemulsions for Simultaneous Delivery of Oxygen and Antioxidants During Machine Perfusion Supported Organ Preservation and demonstrates the role of Microfluidics equipment in the creation of the vital nanoemulsion.

The Critical Need for Advanced Organ Preservation Techniques

Solid organ transplantation (SOT) remains a life-saving treatment for patients suffering from end-stage diseases and organ failure. However, the demand for viable organs far exceeds the supply, with significant challenges in organ preservation contributing to this shortfall. According to the Global Observatory on Donation and Transplantation, nearly 172,409 solid organs were transplanted worldwide in 2023, yet approximately 13,639 patients died while waiting for a transplant.

Ischemia-reperfusion injury (IRI) is a major cause of organ rejection and graft failures, further compounding the issue. Traditional preservation techniques, such as static cold storage, have limited efficacy in preventing IRI. There is an urgent need for advanced preservation methods that can improve organ viability and expand the pool of transplantable organs.

Leveraging Perfluorocarbon Nanoemulsions for Dual-Functionality

Recent advancements in nanomedicine have introduced perfluorocarbon nanoemulsions (PFC-NEs) as a promising solution for organ preservation. PFC-NEs are designed to deliver both oxygen and therapeutic agents simultaneously. These nanoemulsions incorporate perfluorooctyl bromide (PFOB), which provides superior oxygen solubility, and resveratrol (RSV), a natural antioxidant known for its protective effects against IRI.

The dual-functionality of PFC-NEs addresses the critical need for improved oxygen delivery and antioxidant protection during organ preservation. This innovative approach not only enhances the viability of preserved organs but also reduces the risk of IRI, making it a potential game-changer in the field of organ transplantation.

The Role of Microfluidizer^® Processors in Scalable Nanoemulsion Production

The scalable manufacturing of PFC-NEs is a key factor in their potential clinical application. High shear Microfluidizer equipment, such as the Microfluidizer M110S, LM20, and M110P, played a crucial role in producing consistent and stable nanoemulsions. These Microfluidizer^® Processors facilitated the creation of nanoemulsions with a uniform droplet size, essential for nanoemulsion stability and efficacy.

In the research conducted by Smith Patel et al., the use of Microfluidizer^® Technology allowed for the production of PFC-NEs at various scales, ranging from 250 mL to 1000 mL. The study demonstrated that the droplet size and polydispersity index remained consistent across different batch sizes and processing equipment, highlighting the robustness and scalability of the manufacturing process using Microfluidizer^® Processors.

Stability and Oxygen-Carrying Capacity of PFC-NEs

The stability and oxygen-carrying capacity of PFC-NEs are critical for their effectiveness in organ preservation. The research findings indicated that PFC-NEs maintained a consistent droplet size (90-110 nm) and low polydispersity index (<0.3) across all scales, with high reproducibility and >80% PFOB loading.

In both machine perfusion setups and oxygen bubbling methods, PFC-NEs demonstrated superior oxygenation capacity compared to traditional University of Wisconsin (UW) solution. The partial pressure of oxygen (pO2) levels in PFC-NEs consistently exceeded those of the UW solution, indicating their enhanced ability to deliver oxygen during organ preservation.

Benefits of Resveratrol-Loaded Nanoemulsions in Preventing IRI

Resveratrol (RSV), incorporated into the hydrocarbon shell of the PFC-NEs, offers significant antioxidant protection. The study showed that RSV-loaded nanoemulsions (RSV-NEs) provided sustained release of RSV, maintaining higher cell viability and preventing ferroptosis in macrophage cells compared to free RSV solutions.

The antioxidant activity of RSV-NEs was confirmed through the Oxygen Radical Antioxidant Capacity (ORAC) assay, which demonstrated dose-dependent radical scavenging ability. This sustained antioxidant delivery is crucial in mitigating the oxidative stress and lipid peroxidation associated with IRI, thereby improving graft viability during transplantation.

Future Directions: Collaboration and Research Opportunities

The advancements in PFC-NEs for organ preservation present exciting opportunities for further research and collaboration. The scalable production and dual-functionality of these nanoemulsions offer a promising solution to the challenges of organ preservation and transplantation using Microfluidizer^® Technology.

To read the full research paper, please visit https://www.mdpi.com/1999-4923/18/2/143.

Join us in pioneering the next generation of organ preservation solutions. For more information on the Microfluidics products and services, give us a call or contact us.